• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

长期腹腔通路及一种新型通路导管的描述

Long-term intraperitoneal access with description of a new access catheter.

作者信息

Pedro Villarejo Campos, Edward Bruce-White, Mariano García Arranz, Qian Siyuan, Antonio Pedro, Cascales Campos, Damián García Olmo, Alberto Martínez Albalat

机构信息

Department of Surgical Oncology, Jiménez Díaz Foundation Institute for Health Research, Madrid, Spain.

出版信息

J Surg Oncol. 2024 Nov;130(6):1390-1394. doi: 10.1002/jso.27843. Epub 2024 Aug 25.

DOI:10.1002/jso.27843
PMID:39183486
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11826025/
Abstract

BACKGROUND AND OBJECTIVES

Intraperitoneal chemotherapy can be administered as a single dose associated with hyperthermia (HIPEC) or in successive doses under normothermic conditions, such as early postoperative intraperitoneal chemotherapy (EPIC) or normothermic intraperitoneal chemotherapy (NIPEC or NIPEC-LT). Repetitive administration of intraperitoneal chemotherapy over a prolonged period may be associated with catheter-related complications, which are the primary cause of treatment interruption. This study aims to introduce and evaluate an innovative catheter system designed to mitigate these issues.

METHODS

Using a porcine experimental model, we tested a new catheter for long-term intraperitoneal access. Sixteen animals underwent catheter implantation followed by normothermic recirculation of peritoneal dialysis solution. Catheter functionality and any complications were monitored throughout successive treatment cycles.

RESULTS

The new catheter system demonstrated optimal recirculation and maintained its functionality throughout successive treatments, without complications. Catheter replacement with a guidewire was successful, ensuring continued efficacy.

CONCLUSIONS

The innovative catheter system shows promise in reducing complications and improving compliance in successive intraperitoneal chemotherapy doses, justifying further clinical trials to confirm its efficacy in patients.

摘要

背景与目的

腹腔内化疗可作为与热疗联合的单剂量给药（热灌注化疗，HIPEC），也可在常温条件下分多次给药，如术后早期腹腔内化疗（EPIC）或常温腹腔内化疗（NIPEC或NIPEC-LT）。长时间重复进行腹腔内化疗可能会出现与导管相关的并发症，这是治疗中断的主要原因。本研究旨在介绍并评估一种旨在减轻这些问题的创新导管系统。

方法

我们使用猪实验模型测试了一种用于长期腹腔内通路的新型导管。16只动物接受了导管植入，随后进行腹膜透析液的常温再循环。在连续的治疗周期中监测导管功能及任何并发症。

结果

新导管系统在连续治疗过程中显示出最佳的再循环效果，并保持其功能，无并发症发生。通过导丝成功更换导管，确保了持续疗效。

结论

这种创新的导管系统在减少连续腹腔内化疗剂量的并发症和提高依从性方面显示出前景，有理由进行进一步的临床试验以证实其在患者中的疗效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d98/11826025/2f4fa13d41f0/JSO-130-1390-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d98/11826025/7855e739d213/JSO-130-1390-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d98/11826025/135abef52be0/JSO-130-1390-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d98/11826025/2f4fa13d41f0/JSO-130-1390-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d98/11826025/7855e739d213/JSO-130-1390-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d98/11826025/135abef52be0/JSO-130-1390-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d98/11826025/2f4fa13d41f0/JSO-130-1390-g003.jpg

相似文献

1
Long-term intraperitoneal access with description of a new access catheter.长期腹腔通路及一种新型通路导管的描述
J Surg Oncol. 2024 Nov;130(6):1390-1394. doi: 10.1002/jso.27843. Epub 2024 Aug 25.
2
Normothermic intraperitoneal chemotherapy long term (NIPEC-LT) in the management of peritoneal surface malignancy, an overview.常温腹腔内长期化疗（NIPEC-LT）在腹膜表面恶性肿瘤治疗中的概述
Pleura Peritoneum. 2017 Jun 1;2(2):85-93. doi: 10.1515/pp-2017-0012. Epub 2017 May 23.
3
Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival.上皮性恶性腹膜间皮瘤患者的长期区域化疗可提高生存率。
Eur J Surg Oncol. 2017 Jul;43(7):1228-1235. doi: 10.1016/j.ejso.2017.01.009. Epub 2017 Jan 29.
4
Effect of postoperative normothermic intraperitoneal chemotherapy on the prognosis of MPM patients receiving CRS+HIPEC: A single-center case-control study.术后常温腹腔内热化疗对接受 CRS+HIPEC 的 MPM 患者预后的影响：一项单中心病例对照研究。
Eur J Surg Oncol. 2024 Nov;50(11):108692. doi: 10.1016/j.ejso.2024.108692. Epub 2024 Sep 14.
5
[Laparoscopic peritoneal dialysis catheter implantation in peritoneal chemotherapy for gastric cancer with peritoneal metastasis].腹腔镜下腹膜透析导管植入术在胃癌伴腹膜转移腹膜化疗中的应用
Zhonghua Wei Chang Wai Ke Za Zhi. 2019 Aug 25;22(8):774-780. doi: 10.3760/cma.j.issn.1671-0274.2019.08.013.
6
Intraperitoneal delivery of chemotherapeutic agents for the treatment of peritoneal metastases: current challenges and how to overcome them.腹腔内递送化疗药物治疗腹膜转移：当前的挑战及应对策略。
Expert Opin Drug Deliv. 2019 Dec;16(12):1393-1401. doi: 10.1080/17425247.2019.1693997. Epub 2019 Nov 26.
7
Use of acute peritoneal dialysis catheters for intraperitoneal chemotherapy instead of the semipermanent/permanent Tenkhoff catheters.使用急性腹膜透析导管进行腹腔内化疗，而非半永久性/永久性Tenkhoff导管。
Support Care Cancer. 1994 Mar;2(2):132-3. doi: 10.1007/BF00572096.
8
Update on the management of malignant peritoneal mesothelioma.恶性腹膜间皮瘤管理的最新进展
Transl Lung Cancer Res. 2018 Oct;7(5):599-608. doi: 10.21037/tlcr.2018.08.03.
9
Intraperitoneal gemcitabine chemotherapy is safe for patients with resected pancreatic cancer: final clinical and pharmacologic data from a phase II protocol and recommended future directions.腹腔内吉西他滨化疗对已切除胰腺癌患者是安全的：来自一项II期方案的最终临床和药理学数据及推荐的未来研究方向
J Gastrointest Oncol. 2021 Apr;12(Suppl 1):S99-S109. doi: 10.21037/jgo-2020-02.
10
Unusually favorable outcome of 6 consecutive patients with diffuse malignant peritoneal mesothelioma treated with repeated doses of intraperitoneal paclitaxel. A case series.6 例弥漫性恶性腹膜间皮瘤患者反复腹腔内紫杉醇治疗的异常良好结果。病例系列。
Surg Oncol. 2020 Jun;33:96-99. doi: 10.1016/j.suronc.2020.01.009. Epub 2020 Jan 25.

本文引用的文献

1
Cytoreductive surgery plus hyperthermic intraoperative peritoneal chemotherapy for people with peritoneal metastases from colorectal, ovarian or gastric origin: A systematic review of randomized controlled trials.细胞减灭术联合腹腔内热灌注化疗治疗结直肠、卵巢或胃来源腹膜转移患者：随机对照试验的系统评价。
World J Surg. 2024 Jun;48(6):1385-1403. doi: 10.1002/wjs.12186. Epub 2024 Apr 24.
2
HIPEC in Ovarian Cancer Is the Future… and Always Will Be? Results from a Spanish Multicentric Survey.卵巢癌腹腔热灌注化疗是未来的趋势……且将一直如此吗？一项西班牙多中心调查的结果
Cancers (Basel). 2023 Jul 4;15(13):3481. doi: 10.3390/cancers15133481.
3
Optimizing regional chemotherapy for epithelial ovarian cancer.
优化上皮性卵巢癌的区域化疗。
J Obstet Gynaecol Res. 2022 Jun;48(6):1306-1317. doi: 10.1111/jog.15224. Epub 2022 Mar 27.
4
Influence of peritoneal dialysis catheter type on complications and long-term outcomes: an updated systematic review and meta-analysis.腹膜透析导管类型对并发症和长期结局的影响：一项更新的系统评价和荟萃分析。
J Nephrol. 2021 Dec;34(6):1973-1987. doi: 10.1007/s40620-021-01016-y. Epub 2021 Mar 22.
5
An overview and update of hyperthermic intraperitoneal chemotherapy in ovarian cancer.腹腔内热灌注化疗治疗卵巢癌的概述和最新进展。
Expert Opin Pharmacother. 2020 Aug;21(12):1479-1492. doi: 10.1080/14656566.2020.1766024. Epub 2020 Jun 3.
6
Straight Versus Coiled Peritoneal Dialysis Catheters: A Randomized Controlled Trial.直型与卷曲型腹膜透析导管：一项随机对照试验。
Am J Kidney Dis. 2020 Jan;75(1):39-44. doi: 10.1053/j.ajkd.2019.05.024. Epub 2019 Aug 21.
7
Normothermic intraperitoneal chemotherapy long term (NIPEC-LT) in the management of peritoneal surface malignancy, an overview.常温腹腔内长期化疗（NIPEC-LT）在腹膜表面恶性肿瘤治疗中的概述
Pleura Peritoneum. 2017 Jun 1;2(2):85-93. doi: 10.1515/pp-2017-0012. Epub 2017 May 23.
8
Peritoneal Metastases from Colorectal Cancer: Treatment Principles and Perspectives.结直肠癌腹膜转移：治疗原则与展望
Surg Oncol Clin N Am. 2018 Jul;27(3):563-583. doi: 10.1016/j.soc.2018.02.011.
9
Update on Intraperitoneal Chemotherapy for the Treatment of Epithelial Ovarian Cancer.上皮性卵巢癌腹腔内化疗的最新进展
Am Soc Clin Oncol Educ Book. 2016;35:143-51. doi: 10.1200/EDBK_158927.
10
Peritoneal carcinomatosis: cytoreductive surgery and HIPEC--overview and basics.腹膜癌病：细胞减灭术和 HIPEC-概述和基础。
Cancer Invest. 2012 Mar;30(3):209-24. doi: 10.3109/07357907.2012.654871.